Current perspectives on HIV-associated lipodystrophy syndrome

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 6-9

  Milinkovic, Ana ^a   Martinez, Esteban ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Body fat changes; Definition; Metabolic abnormalities; Structured treatment interruptions; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIRETROVIRUS AGENT; GEMFIBROZIL; LEPTIN; METFORMIN; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; ROSIGLITAZONE; STAVUDINE; THYMIDINE DERIVATIVE;

ARTICLE; BODY COMPOSITION; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FOLLOW UP; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOSUCTION; PLASTIC SURGERY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 24044508934     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki165     Document Type: Article

References (58)

1. Carr A, Samaras K, Burton S [i#et al.#1i] A syndrome of peripheral lipodystrophy hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. [i#AIDS#1i] 1998; [b#12#1b]: F51-8.
2. Heath K, Hogg RS, Chan KJ [i#et al.#1i] Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. [i#AIDS#1i] 2001; [b#15#1b]: 231-9.
3. Friis-Moller N, Weber R, Reiss P [i#et al.#1i] Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. [i#AIDS#1i] 2003; [b#17#1b]: 1179-93.
4. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: A case control study. [i#Lancet#1i] 2003; [b#361#1b]: 726-35.
5. Grunfeld C. Basic science and metabolic disturbances. In: [i#Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002#1i]. Abstract TuOr158. IAS International AIDS Society, Geneva, Switzerland.
6. Kotler DP. [i#Update on Lipodystrophy. Or Is It Just Lipoatrophy? (2002) Medscape. HIV/AIDS.#1i] http://www.medscape.com/viewarticle/ 439480?src=search (16 May 2005, date last accessed).
7. Gripshover B, Tien PC, Saag M [i#et al.#1i] Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected man. In: [i#Programs and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2003#1i]. Abstract 732, p. 319. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Saint-Marc T, Partisani M, Poizot-Martin I [i#et al.#1i] Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiviral therapy: Preliminary results of the LIPOCO study. [i#AIDS#1i] 2000; [b#14#1b]: 37-49.
9. Enzi G, Gasparo M, Biondetti PR [i#et al.#1i] Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. [i#Am J Clin Nutr#1i] 1986; [b#44#1b]: 739-46.
10. Asensi V, Martin-Roces E, Carton JA [i#et al.#1i] Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiviral therapy. [i#Clin Infect Dis#1i] 2004; [b#39#1b]: 240-7.
11. Martinez E, Bianchi L, Garcia MA [i#et al.#1i] Sonographic assessment of regional fat in HIV-infected persons. [i#Lancet#1i] 2000; [b#356#1b]: 1412-13.
12. Wanke CA. Epidemiological and clinical aspects of metabolic complications of HIV infection: The fat redistribution syndrome. [i#AIDS#1i] 1999; [b#13#1b]:1287-93.
13. Milinkovic A, Vidal S, Bianchi L [i#et al.#1i] Comparative assessment of objective methods for the measurement of body fat. [i#Antivir Ther#1i] 2003; [b#8#1b]: L63.
14. Batterham M, Garsia R, Greenop P [i#et al.#1i] Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy 'Diet FRS Study'. [i#AIDS#1i] 2000; [b#14#1b] 1839-43.
15. Roubenoff R, Weiss L, McDermott A [i#et al.#1i] A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat distribution. [i#AIDS#1i] 1999; [b#13#1b]: 1373-5.
16. Smith BA, Neidig J, Nickel J [i#et al.#1i] Aerobic exercise: Effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. [i#AIDS#1i] 2001; [b#15#1b]: 693-701.
17. Bickel M, Zangos S, Jacobi V [i#et al.#1i] Effects of recombinant human growth hormone (r-hGH) on fat depletion and plasma lipids in HIV-1-infected patients with lipodystrophy - a randomized, open-label study. In: [i#Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005#1i]. Abstract 855, p. 384. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. Engelson ES, Glesby MJ, Mendez D [i#et al.#1i] Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. [i#J Acquir Immune Defic Syndr#1i] 2002; [b#30#1b]: 379-91.
19. Lo JC, Mulligan K, Noor MA [i#et al.#1i] The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. [i#J Clin Endocrin Metab#1i] 2001; [b#86#1b]:3480-7.
20. Martinez E, Mocroft A, Garcia-Viejo MA [i#et al.#1i] Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. [i#Lancet#1i] 2001; [b#357#1b]: 592-8.
21. Lichtnestein KA, Delaney KM, Armon C [i#et al.#1i] Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. [i#J Acquir Immune Defic Syndr#1i] 2003; [b#32#1b]: 48-56.
22. Galli M, Cozzi-Lepri A, Ridolfo AL [i#et al.#1i] Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipolCoNa Study. [i#Arch Intern Med#1i] 2002; [b#162#1b]: 2621-8.
23. Saag MS, Cahn P, Raffi F [i#et al.#1i] Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial. [i#JAMA#1i] 2004; [b#292#1b]: 180-9.
24. Gallant J, Staszewski S, Pozniak AL [i#et al.#1i] Long-term efficacy and safety of tenofovir disoproxil fumarate (TDF): A 144-week comparison versus stavudine (d4T) in antiretroviral-naive patients. [i#JAMA#1i] 2004; [b#292#1b]: 191-201.
25. Walmsley S, Horban A, Jain R [i#et al.#1i] Fosamprenavir/ritonavir and nelfinavir have comparable effects on body fat changes in antiretroviral-naive patients: 48-week results from the SOLO study. [i#Antivir Ther#1i] 2004; [b#9#1b]: L37.
26. Shlay JC, Visnegarwala F, Bartsch G [i#et al.#1i] Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. [i#J Acquir Immune Defic Syndr#1i] 2005; [b#38#1b]: 147-55.
27. Martinez E, Arnaiz JA, Podzamcer D [i#et al.#1i] Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. [i#N Engl J Med#1i] 2003; [b#349#1b]: 1036-46.
28. Carr A, Hudson J, Chau J [i#et al.#1i] HIV protease inhibitor substitution in patients with lipodystrophy: Randomised, controlled, open-label, multicentre study. [i#AIDS#1i] 2001; [b#15#1b]: 1811-22.
29. Martin A, Smith DE, Ringland C [i#et al.#1i] Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX extension study. [i#AIDS#1i] 2004; [b#18#1b] 1029-36.
30. McComsey GA, Ward DJ, Hessenthaler SM [i#et al.#1i] Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. [i#Clin Infect Dis#1i] 2004; [b#38#1b]: 263-70.
31. John M, McKinnon EJ, James IR [i#et al.#1i] Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. [i#J Acquir Immune Defic Syndr#1i] 2003; [b#33#1b]: 29-33.
32. Moyle GJ, Baldwin C, Langroudi B [i#et al.#1i] A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. [i#J Acquir Immune Defic Syndr#1i] 2003; [b#33#1b]: 22-8.
33. Moyle G, Sabin C, Cartledge J [i#et al.#1i] A 48-week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. In: [i#Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005#1i]. Abstract 44LB, p. 81. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
34. Milinkovic A, Lopez S, Vidal S [i#et al.#1i] A randomized open study comparing the effect of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. In: [i#Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005#1i]. Abstract 857, p. 384. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
35. Milinkovic A, Martinez E, Vidal S [i#et al.#1i] Impact of structured therapy interruption on body composition of chronically HIV-infected patients: Preliminary 1-year results. [i#Antivir Ther#1i] 2003; [b#8#1b]: L61.
36. Maggiolo F, Ripamonti D, Gregis G [i#et al.#1i] Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. [i#AIDS#1i] 2004; [b#18#1b]: 439-46.
37. Arioglu E, Duncan Morin J, Sebring NG. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. [i#Ann Intern Med#1i] 2000; [b#133#1b]: 263-74.
38. Petersen KF, Oral EA, Dufour S [i#et al.#1i] Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. [i#J Clin Invest#1i] 2002; [b#109#1b]: 1345-50.
39. Oral E, Simha V, Ruiz E [i#et al.#1i] Leptin-replacement therapy for lipodystrophy. [i#N Engl J Med#1i] 2002; [b#346#1b]: 570-8.
40. Gelato MC, Mynarick DC, Quick JL [i#et al.#1i] Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot study. [i#J Acquir Immune Defic Syndr#1i] 2002; [b#31#1b]: 163-70.
41. Sutinen J, Hakkinen AM, Westerbacka J [i#et al.#1i] Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo controlled study. [i#Antivir Ther#1i] 2003; [b#8#1b]: 199-207.
42. Carr A, Workman C, Carey D [i#et al.#1i] No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. [i#Lancet#1i] 2004; [b#363#1b]: 429-38.
43. Mallon P, Sedwell GR, Rogers G [i#et al.#1i] The effect of rosiglitazone on PPAR-γ expression in human adipose tissue is limited by continued exposure to thymidine NRTI. In: [i#Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005#1i]. Abstract 41, p. 79. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
44. Martínez E, Domingo P, Ribera E [i#et al.#1i] Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. [i#Antivir Ther#1i] 2003; [b#8#1b]: 403-10.
45. Hadigan C, Corcoran C, Basgoz N [i#et al.#1i] Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. [i#JAMA.#1i] 2000; [b#284#1b]: 472-7.
46. Driscoll SD, Meininger GE, Lareau MT [i#et al.#1i] Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. [i#AIDS#1i] 2004; [b#18#1b]: 465-73.
47. Schambelan M, Benson C, Carr A [i#et al.#1i] Management of metabolic complications associated with antiviral therapy for HIV-infection: recommendations of an International AIDS Society-USA Panel. [i#J Acquir Immune Defic Syndr#1i] 2003; [b#31#1b]: 257-75.
48. Ponce-De-Leon S, Iglesias M, Ceballos J [i#et al.#1i] Liposuction for protease-inhibitor associated lipodystrophy. [i#Lancet#1i] 1999; [b#353#1b] 1244.
49. Wolfort FG, Cetrulo CL, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. [i#Plast Reconstr Surg#1i] 1999; [b#104#1b]: 1814-20.
50. Valantin MA, Aubron-Olivier C, Ghosn J [i#et al.#1i] Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. [i#AIDS#1i] 2003; [b#17#1b] 2471-7.
51. Moyle G, Lysakova L, Brown S [i#et al.#1i] A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. [i#HIV Med#1i] 2004; [b#5#1b]: 82-7.
52. US Food and Drug Administration. [i#FDA aproves Sculptra for HIV Patients#1i]. http://www.fda.gov/bbs/topics/news/2004/NEW01100.html (16 May 2005, date last accessed).
53. Ritt MJ, Hillebrand-Haverkort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. [i#Acta Chir Plast#1i] 2001; [b#43#1b]: 54-6.
54. Protopopa C, Sito G, Caporale D [i#et al.#1i] Bio-Alcamide in drug induced lipodystrophy. [i#J Cosmet Laser Ther#1i] 2003; [b#5#1b]: 226-30.
55. Guaraldi G, Orlando G, De fazio D [i#et al.#1i] Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy. [i#Antivir Ther#1i] 2004; [b#9#1b]: L9.
56. Fontdevilla J, Milinkovic A, Martinez E [i#et al#1i] Treatment of facial lipoatrophy by injection of autologous adipose tissue. [i#Antivir Ther#1i] 2003; [b#8#1b]: L76.
57. Serra-Renom JM, Fontdevila J. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. [i#Plast Reconstr Surg#1i] 2004; [b#114#1b]: 551-5.
58. Guaraldi G, De Fazio D, Orlando G [i#et al.#1i] Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. [i#Clin Infect Dis#1i] 2005; [b#40#1b]: 13-5.